Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2477252rdf:typepubmed:Citationlld:pubmed
pubmed-article:2477252lifeskim:mentionsumls-concept:C0229951lld:lifeskim
pubmed-article:2477252lifeskim:mentionsumls-concept:C0814999lld:lifeskim
pubmed-article:2477252lifeskim:mentionsumls-concept:C0063695lld:lifeskim
pubmed-article:2477252lifeskim:mentionsumls-concept:C0081942lld:lifeskim
pubmed-article:2477252lifeskim:mentionsumls-concept:C0079717lld:lifeskim
pubmed-article:2477252lifeskim:mentionsumls-concept:C0108779lld:lifeskim
pubmed-article:2477252lifeskim:mentionsumls-concept:C1704675lld:lifeskim
pubmed-article:2477252lifeskim:mentionsumls-concept:C0443208lld:lifeskim
pubmed-article:2477252lifeskim:mentionsumls-concept:C1367475lld:lifeskim
pubmed-article:2477252lifeskim:mentionsumls-concept:C1167622lld:lifeskim
pubmed-article:2477252lifeskim:mentionsumls-concept:C1145667lld:lifeskim
pubmed-article:2477252pubmed:issue9lld:pubmed
pubmed-article:2477252pubmed:dateCreated1989-11-22lld:pubmed
pubmed-article:2477252pubmed:abstractTextIn view of the necessity for thymocytes to interact with thymic epithelial cells to differentiate into mature T cells, this study analyzed the binding between human thymocytes, cultured thymic epithelial cells (CTEC) and the required adhesion molecules. Immediately after separation, thymic epithelial cells (TEC) readily expressed ICAM-1, which is one of the ligands of LFA-1 cell adhesion molecules. However, the ICAM-1 expression was gradually lost upon culture of TEC. IFN-gamma re-induced ICAM-1 on the CTEC, and the ability of CTEC to bind to thymocytes was also increased by IFN-gamma treatment. The increase in binding seemed to be caused by the LFA-1/ICAM-1 interaction, since it was inhibited by anti-ICAM-1 monoclonal antibody (mAb) and anti-LFA-1 mAb. This suggests that the LFA-1/ICAM-1 interaction is also involved in vivo with the binding of thymocytes to TEC, which have been shown to express ICAM-1. To better understand the nature of the cells involved in binding, thymocytes were sorted into CD3-, CD3dull+, and CD3bright+ subsets (which are supposed to represent the immature, intermediate and mature stages of differentiation, respectively), and were examined for their binding to IFN-gamma-treated CTEC. The result showed that only the CD3dull+ subset bound to CTEC. CD3-, CD3bright+ cells and peripheral blood T lymphocytes did not bind, but they were induced to bind by neuramidase treatment All these bindings were inhibited by anti-LFA-1 mAb and anti-CD2 mAb. These findings indicate that CD3dull+ cells can bind to TEC via CD2/LFA-3 and LFA-1/ICAM-1 interactions. Other cells seemed not to bind to TEC because of sialylation.lld:pubmed
pubmed-article:2477252pubmed:languageenglld:pubmed
pubmed-article:2477252pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2477252pubmed:citationSubsetIMlld:pubmed
pubmed-article:2477252pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2477252pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2477252pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2477252pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2477252pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2477252pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2477252pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2477252pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2477252pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2477252pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2477252pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2477252pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2477252pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2477252pubmed:statusMEDLINElld:pubmed
pubmed-article:2477252pubmed:monthSeplld:pubmed
pubmed-article:2477252pubmed:issn0014-2980lld:pubmed
pubmed-article:2477252pubmed:authorpubmed-author:NakayamaMMlld:pubmed
pubmed-article:2477252pubmed:authorpubmed-author:YataJJlld:pubmed
pubmed-article:2477252pubmed:authorpubmed-author:NonoyamaSSlld:pubmed
pubmed-article:2477252pubmed:authorpubmed-author:ShioharaTTlld:pubmed
pubmed-article:2477252pubmed:issnTypePrintlld:pubmed
pubmed-article:2477252pubmed:volume19lld:pubmed
pubmed-article:2477252pubmed:ownerNLMlld:pubmed
pubmed-article:2477252pubmed:authorsCompleteYlld:pubmed
pubmed-article:2477252pubmed:pagination1631-5lld:pubmed
pubmed-article:2477252pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2477252pubmed:meshHeadingpubmed-meshheading:2477252-...lld:pubmed
pubmed-article:2477252pubmed:meshHeadingpubmed-meshheading:2477252-...lld:pubmed
pubmed-article:2477252pubmed:meshHeadingpubmed-meshheading:2477252-...lld:pubmed
pubmed-article:2477252pubmed:meshHeadingpubmed-meshheading:2477252-...lld:pubmed
pubmed-article:2477252pubmed:meshHeadingpubmed-meshheading:2477252-...lld:pubmed
pubmed-article:2477252pubmed:meshHeadingpubmed-meshheading:2477252-...lld:pubmed
pubmed-article:2477252pubmed:meshHeadingpubmed-meshheading:2477252-...lld:pubmed
pubmed-article:2477252pubmed:meshHeadingpubmed-meshheading:2477252-...lld:pubmed
pubmed-article:2477252pubmed:meshHeadingpubmed-meshheading:2477252-...lld:pubmed
pubmed-article:2477252pubmed:meshHeadingpubmed-meshheading:2477252-...lld:pubmed
pubmed-article:2477252pubmed:meshHeadingpubmed-meshheading:2477252-...lld:pubmed
pubmed-article:2477252pubmed:meshHeadingpubmed-meshheading:2477252-...lld:pubmed
pubmed-article:2477252pubmed:meshHeadingpubmed-meshheading:2477252-...lld:pubmed
pubmed-article:2477252pubmed:meshHeadingpubmed-meshheading:2477252-...lld:pubmed
pubmed-article:2477252pubmed:meshHeadingpubmed-meshheading:2477252-...lld:pubmed
pubmed-article:2477252pubmed:meshHeadingpubmed-meshheading:2477252-...lld:pubmed
pubmed-article:2477252pubmed:meshHeadingpubmed-meshheading:2477252-...lld:pubmed
pubmed-article:2477252pubmed:meshHeadingpubmed-meshheading:2477252-...lld:pubmed
pubmed-article:2477252pubmed:meshHeadingpubmed-meshheading:2477252-...lld:pubmed
pubmed-article:2477252pubmed:year1989lld:pubmed
pubmed-article:2477252pubmed:articleTitleOnly dull CD3+ thymocytes bind to thymic epithelial cells. The binding is elicited by both CD2/LFA-3 and LFA-1/ICAM-1 interactions.lld:pubmed
pubmed-article:2477252pubmed:affiliationDepartment of Immunology, National Children's Medical Research Center, Tokyo, Japan.lld:pubmed
pubmed-article:2477252pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2477252pubmed:publicationTypeIn Vitrolld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2477252lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2477252lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2477252lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2477252lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2477252lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2477252lld:pubmed